research-memo-declaratory-judgment-standards.docx

1018-00007 · Penterra Pharmaceuticals Corp · Motions Practice

research-memo-declaratory-judgment-standards.docx DOCUMENT Litigation

18 / 35 ← → ✕

Contract analysis Extract to table

CALDERWOOD & HARKNESS LLP 1 Federal Street, 35th Floor Boston, Massachusetts 02110

INTERNAL MEMORANDUM

TO: Linda Osei, Responsible Partner Priya Anand, Billing Partner Hannah Brinkley, Lead Associate

FROM: Patrick Gallagher, Working Associate

DATE: April 5, 2021

RE: Massachusetts Declaratory Judgment Standards and Ripeness — Penterra Pharmaceuticals Corp. v. Vantage Medical Distribution, LLC

Matter No.: 1018-00007

Docket No.: 2184-CV-01537-BLS (MA Superior Court, Business Litigation Session, Suffolk County)

Right-click to update Table of Contents

I. Introduction and Purpose of Memorandum

This memorandum analyzes whether the declaratory-judgment action filed by Penterra Pharmaceuticals Corp. ("Penterra" or "PPC") on April 12, 2021, in the Superior Court of Massachusetts, Business Litigation Session, Suffolk County, satisfies the statutory requirements for declaratory relief under Massachusetts General Laws chapter 231A, §§ 1–3. The purpose of this memorandum is to provide the litigation team with a comprehensive assessment of the threshold legal standards governing declaratory relief in Massachusetts and to evaluate our client's position in the event Vantage Medical Distribution, LLC ("Vantage") raises a preliminary challenge to the propriety of the declaratory-judgment action on grounds of ripeness, standing, or the availability of alternative remedies.

Penterra's complaint seeks a judicial declaration that Vantage has no exclusive distribution rights beyond the six New England states — Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont — as defined in Exhibit A to the Exclusive Distribution Agreement dated July 1, 2017 (the "EDA"). The complaint further seeks a declaration that Vantage's distribution of Oncalaris® (pegvisomant-axel) in New York, New Jersey, and Pennsylvania (collectively, the "Tri-State Area") is unauthorized under the EDA and constitutes a material breach of Vantage's obligations thereunder.

This memorandum addresses five principal subjects: (1) the statutory framework for declaratory judgment in Massachusetts under G.L. c. 231A; (2) the "actual controversy" requirement and its application to the facts of this matter; (3) the ripeness doctrine and its two-pronged inquiry under Massachusetts law; (4) Penterra's standing to seek declaratory relief as a party to the EDA; and (5) an analysis of the potential threshold challenges Vantage may raise, together with recommended responses.

Summary Conclusion: Based on the analysis below, it is my assessment that Penterra's declaratory-judgment claim is well-suited for declaratory relief and should survive any challenge by Vantage on jurisdictional, ripeness, or standing grounds. The dispute between the parties involves a concrete, definite, and presently existing controversy over the interpretation of a fully executed written contract, and the parties have taken irreconcilable positions supported by concrete commercial actions and substantial financial stakes. The litigation team should proceed with confidence in the procedural propriety of the action and prepare to defend the declaratory-judgment framework in any threshold motion practice.

II. Statutory Framework: G.L. c. 231A

A. Text of the Statute

Massachusetts General Laws chapter 231A provides the statutory basis for declaratory relief in the Commonwealth. The relevant provisions are as follows:

Section 1 provides, in pertinent part:

"The supreme judicial court, the superior court, the land court, and the probate courts, within their respective jurisdictions, may on appropriate proceedings make binding declarations of right, duty, status and other legal relations sought thereby, either before or after a breach or violation thereof, and such proceedings shall not be open to objection on the ground that a merely declaratory judgment or decree is sought thereby and such declaration, when made, shall have the force of a final judgment or decree and be reviewable as such . . . ."

G.L. c. 231A, § 1. This section establishes the authority of the Superior Court — the tribunal in which Penterra's action is pending — to render binding declarations of right. Critically, the statute permits such declarations "either before or after a breach or violation," which confirms that a party need not wait until a breach has occurred or damages have been sustained before seeking declaratory relief. This is directly relevant here, as Penterra seeks both prospective clarity (regarding its right to appoint other distributors in the Tri-State Area) and a declaration regarding past conduct (Vantage's allegedly unauthorized distribution since September 2020).

Section 1 further provides that declarations made under the statute "shall have the force of a final judgment or decree." This means that a declaratory judgment construing the EDA would be binding on both Penterra and Vantage, would be enforceable through contempt proceedings if necessary, and would be reviewable on appeal as a final judgment. The finality provision underscores the Legislature's intent that declaratory relief serve as a meaningful and self-sufficient remedy, not merely an advisory or precatory opinion.

Section 2 expands on the scope of declaratory relief available:

"Any person claiming a present legal or equitable right or title may maintain a petition or action in the appropriate court to determine the same, and the court may make a binding declaration of such right or title, whether or not any consequential relief is or could be claimed, including the determination of any question of construction or validity arising under any instrument, statute, ordinance, contract or franchise and a declaration of the rights, status or other legal relations of any party thereunder."

G.L. c. 231A, § 2. Section 2 is of particular importance to this matter because it expressly authorizes declarations of rights arising under a "contract" and permits the court to resolve "any question of construction" arising under that contract. The dispute between Penterra and Vantage is precisely the kind of contract-construction dispute that Section 2 was designed to address — the parties disagree about the proper interpretation of the Territory as defined in Section 2.1 and Exhibit A of the EDA, and the consequences of that disagreement are playing out in real commercial activity across the northeastern United States.

Equally important, Section 2 provides that declaratory relief may be granted "whether or not any consequential relief is or could be claimed." This language confirms that the availability of alternative remedies — such as a breach-of-contract action for damages — does not preclude declaratory relief. As discussed in Section VI.A below, Vantage may attempt to argue that Penterra should have pursued coercive relief instead; Section 2 forecloses that argument.

Section 3 addresses the court's discretion to decline declaratory relief:

"The court may refuse to make a binding declaration of right, duty, status or other legal relation where such declaration, if made, would not terminate the uncertainty or controversy giving rise to the proceeding."

G.L. c. 231A, § 3. Section 3 grants the court discretion to refuse declaratory relief where the declaration would not resolve the underlying controversy. This provision is a safeguard against piecemeal litigation and advisory opinions. In the present case, however, the declaration sought by Penterra would squarely resolve the central dispute — the scope of Vantage's Territory — and would provide both parties with the clarity needed to govern their commercial conduct going forward. A declaration that the Territory is limited to the six New England states enumerated in Exhibit A would terminate the controversy over whether Vantage has the right to distribute Oncalaris® in the Tri-State Area and would enable Penterra to proceed with the Meridian arrangement or other distribution partnerships in those states.

Finally, it is well established that G.L. c. 231A is remedial in nature and is to be liberally construed to settle and afford relief from uncertainty and insecurity with respect to rights, duties, status, and other legal relations. See Morrissey v. New England Deaconess Ass'n, 358 Mass. 764, 766 (1971); Bunker Hill Distrib., Inc. v. District Attorney for the Suffolk Dist., 376 Mass. 142, 144 (1978). Courts are instructed to resolve doubts about the availability of declaratory relief in favor of entertaining the action, consistent with the remedial purposes of the statute.

B. Scope and Discretion

Massachusetts courts have broad discretion under G.L. c. 231A to determine whether declaratory relief is appropriate in a given case. That discretion, however, is not unfettered. Where a genuine controversy exists between parties with adverse legal interests, and where the declaration sought would terminate the uncertainty giving rise to the proceeding, courts are expected to exercise their discretion in favor of granting relief. See Bunker Hill Distrib., 376 Mass. at 144–45; Boston Safe Deposit & Trust Co. v. Stratton, 259 Mass. 465, 470 (1927).

It is important to note that G.L. c. 231A does not itself create subject-matter jurisdiction. Rather, the statute provides a remedy — declaratory relief — that is available in courts of competent jurisdiction. Jurisdiction must exist independently, either through the general jurisdictional provisions applicable to the tribunal in question or through the parties' consent. In this case, jurisdiction in the Superior Court is well established on multiple independent grounds. First, Section 14.5 of the EDA provides that the parties consent to the exclusive jurisdiction of the "state or federal courts located in the Commonwealth of Massachusetts" for any disputes arising under the agreement. Second, Vantage is a Massachusetts limited liability company with its principal place of business at 75 Cabot Road, Suite 310, Medford, Massachusetts 02155, and is therefore subject to general jurisdiction in Massachusetts. Third, Penterra maintains a registered agent for service of process in Massachusetts through CT Statutory Agent Services at 155 Federal Street, Suite 700, Boston, Massachusetts 02110, and has consented to jurisdiction through the forum-selection clause. No jurisdictional deficiency exists.

The court may decline declaratory relief where another remedy is more appropriate, but Massachusetts courts exercise this discretion sparingly in cases involving genuine contract disputes. See Shapiro v. Sutherland, 64 Mass. App. Ct. 27, 36 (2005) (observing that declaratory relief is well-suited to resolving contract-construction disputes). Contract-interpretation cases present paradigmatic circumstances for declaratory relief: the relevant instruments are fixed, the parties' positions are defined, and the court can render a declaration that provides immediate and lasting clarity to both sides.

III. The "Actual Controversy" Requirement

A. Legal Standard

The central prerequisite for declaratory relief under G.L. c. 231A is the existence of an "actual controversy." The Supreme Judicial Court has consistently held that the statute does not authorize courts to render advisory opinions or to decide hypothetical questions; there must be a real and substantial dispute between parties with genuinely adverse legal interests. See Bunker Hill Distrib., Inc. v. District Attorney for the Suffolk Dist., 376 Mass. 142, 144–45 (1978); Boston v. Keene Corp., 406 Mass. 301, 304 (1989).

In Bunker Hill Distribution, the Supreme Judicial Court set forth the governing standard: the controversy must involve "definite and concrete" issues between "parties having adverse legal interests." 376 Mass. at 144–45. The Court further explained that the dispute must be "of sufficient immediacy and reality to warrant the issuance of a declaratory judgment." Id. This formulation requires something more than a theoretical disagreement or a speculative future conflict; the parties must be engaged in a present controversy with concrete stakes.

In Lockwood v. Commissioner of Revenue, 379 Mass. 674, 677 (1980), the Supreme Judicial Court elaborated on this standard, holding that the controversy must be "ripe" for judicial resolution and not merely advisory in nature. The Court in Lockwood emphasized that the actual-controversy requirement serves two related purposes: it prevents courts from issuing opinions on abstract questions of law, and it ensures that judicial resources are directed to disputes where a declaration will have practical consequences for the parties. Id. at 677–78.

Several additional principles inform the actual-controversy analysis. First, the action may be maintained even though the plaintiff could have sought coercive relief, such as damages for breach of contract. Declaratory judgment is an independent remedy available under G.L. c. 231A, § 2, "whether or not further relief is or could be claimed." The plaintiff is not required to demonstrate that declaratory relief is the only remedy available; it need only demonstrate that a genuine controversy exists and that declaratory relief would serve to resolve it. Second, Massachusetts courts regularly entertain declaratory-judgment actions to construe contracts, including exclusive distribution agreements, franchise agreements, licensing agreements, and other commercial instruments. See, e.g., Sullivan v. Chief Justice for Admin. & Mgmt. of the Trial Court, 448 Mass. 15, 22–23 (2006); Cambridge Biotech Corp. v. Pasteur Falveris Diagnostics, 433 Mass. 122 (2000) (addressing contract interpretation in declaratory-judgment posture).

The existence of a counterclaim by the defendant — far from defeating the declaratory-judgment action — typically confirms the existence of an actual controversy. Where both parties have staked out adverse positions and each claims affirmative rights under the contract, the controversy is, if anything, more sharply defined.

B. Application to This Matter

The dispute between Penterra and Vantage satisfies the "actual controversy" requirement in every respect. The controversy is actual, concrete, definite, and of sufficient immediacy and reality to warrant declaratory relief.

Vantage's commencement of Tri-State distribution. The controversy is not a matter of speculation or hypothetical planning. Vantage began shipping Oncalaris® to hospitals and oncology clinics in New York, New Jersey, and Pennsylvania on or about September 14, 2020. According to Penterra's internal commercial intelligence reports (provided to this firm as part of the initial client intake), Vantage generated approximately $6.4 million in Tri-State revenues through March 2021. These shipments were made to at least fourteen hospital systems and oncology practice groups across the three states, including major accounts at NewYork-Presbyterian Hospital, Harborline Industries, and the Hospital of the University of Pennsylvania. Vantage's Tri-State distribution activities are thus not prospective or contingent; they represent a substantial, ongoing course of commercial conduct that Penterra asserts is unauthorized under the EDA.

Penterra's cease-and-desist demand. On March 8, 2021, Penterra's General Counsel, Jennifer Chao, sent a formal cease-and-desist letter to Vantage CEO Donald R. Farnham, demanding that Vantage immediately cease distributing Oncalaris® outside the six New England states identified in Exhibit A to the EDA. The letter stated Penterra's position unequivocally: Vantage's Territory is limited to the six New England states, and any distribution outside that Territory constitutes a material breach of Section 2.3 of the EDA, which prohibits the Distributor from soliciting or delivering product outside the Territory without the prior written consent of the Supplier.

Vantage's adversarial response. On March 22, 2021, Vantage's outside counsel, Kenneth M. Rourke of Hargrove, Sinclair & Polk LLP, responded to Penterra's cease-and-desist letter with a detailed eleven-page letter asserting that Vantage possessed exclusive distribution rights in the Tri-State Area. Specifically, Mr. Rourke's letter contended that an email dated January 12, 2018, from Steven Kapoor, Penterra's Vice President of Commercial Operations, to Donald Farnham, constituted "prior written consent" under Section 2.3 of the EDA — or, alternatively, a written amendment to the Territory under Section 13.1 — authorizing Vantage to distribute Oncalaris® in the Tri-State Area. The letter further threatened that Vantage would pursue a breach-of-contract and tortious interference counterclaim seeking no less than $35 million in damages if Penterra appointed a competing distributor in those states. The March 22 letter left no doubt that the parties' positions are diametrically opposed.

The stalled Meridian arrangement. Penterra had executed a binding term sheet with Meridian National Distributors, Inc. on February 15, 2021, contemplating an exclusive distribution arrangement for Oncalaris® in New York, New Jersey, Pennsylvania, and Maryland. The Meridian term sheet, which was negotiated by Penterra's VP of Strategic Partnerships, included a 90-day exclusivity period for the negotiation of a definitive distribution agreement. However, the Meridian transaction has stalled as a direct consequence of Vantage's assertion of territorial rights in the Tri-State Area. Meridian's counsel has indicated that Meridian will not proceed to a definitive agreement until the territorial dispute with Vantage is resolved. The stalled Meridian arrangement represents a concrete, ongoing commercial harm to Penterra that can only be remedied through judicial clarification of the parties' rights under the EDA.

The contractual provisions in dispute. The parties have taken concrete, adverse positions on the interpretation of specific provisions of the EDA, including:

• Section 2.1 (Grant of Exclusive Territory): This section grants Vantage the exclusive right to distribute Oncalaris® within the "Territory" as defined in Exhibit A.

• Exhibit A (Territory Definition): Exhibit A identifies the Territory as the states of Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont — and no other states.

• Section 2.3 (Limitation on Solicitation/Delivery Outside the Territory): This section provides that the Distributor "shall not, directly or indirectly, solicit orders for, market, sell, or deliver the Products to any customer or end user located outside the Territory without the prior written consent of the Supplier."

• Section 13.1 (Written Amendment Requirement): This section provides that "no amendment, modification, or waiver of any provision of this Agreement shall be valid unless set forth in a written instrument signed by both parties."

• Section 14.8 (Integration Clause): This section provides that the EDA "constitutes the entire agreement of the parties with respect to the subject matter hereof and supersedes all prior agreements, negotiations, and understandings, whether oral or written."

Vantage's position rests on its claim that the January 12, 2018 Kapoor Email constituted either "prior written consent" under Section 2.3 or an amendment to the Territory under Section 13.1. Penterra disputes this characterization and contends that the Kapoor Email — which appears to have discussed the possibility of future expansion into the Tri-State Area — did not constitute either consent or an amendment. The integration clause in Section 14.8 and the written-amendment requirement in Section 13.1 further support Penterra's position. The substance of these arguments will be developed in a separate memorandum on written-modification clauses and course of dealing under Massachusetts law.

Financial stakes. The controversy is not hypothetical; real commercial activity and real money are at stake. Vantage has generated approximately $6.4 million in disputed Tri-State revenues since September 2020. Vantage has threatened a $35 million counterclaim. The Meridian distribution deal — which would open significant new markets for Oncalaris® in the Mid-Atlantic region — remains stalled. Oncalaris® generated approximately $412 million in fiscal year 2021 revenue, representing approximately 22% of Penterra's $1.87 billion consolidated revenue. The financial materiality of this dispute is beyond question.

In sum, the parties have taken definite, concrete, and irreconcilable positions on the interpretation of the EDA, and those positions are backed by substantial commercial activity and financial exposure. This is precisely the type of dispute that declaratory relief under G.L. c. 231A was designed to resolve.

IV. Ripeness

A. Legal Standard

The ripeness doctrine ensures that courts do not issue advisory opinions or decide disputes prematurely, before the issues are sufficiently crystallized for judicial resolution. Ripeness is closely related to the "actual controversy" requirement but focuses more specifically on the timing and maturity of the dispute.

Under Massachusetts law, the ripeness inquiry involves two prongs:

First, fitness for judicial resolution. The court asks whether the issue presented is primarily legal in nature or whether it requires further factual development before judicial resolution would be appropriate. Contract-interpretation disputes are typically fit for judicial resolution because they raise predominantly legal questions that can be resolved on the face of the contract and the undisputed surrounding circumstances. See Massachusetts Ass'n of Indep. Agents & Brokers, Inc. v. Commissioner of Ins., 373 Mass. 290, 293 (1977). Where the relevant contractual instruments are fully executed and available for the court's review, and where the parties' positions can be evaluated based on the language of those instruments, the dispute is fit for judicial resolution without the need for further factual development.

Second, hardship to the parties of withholding review. The court asks whether declining to review the dispute would cause concrete harm to one or both parties. Where a party faces ongoing commercial injury, uncertainty that impedes business decisions, or exposure to substantial legal liability, the hardship of withholding review weighs in favor of finding the dispute ripe. See id. at 293–94.

The Supreme Judicial Court addressed these principles in Massachusetts Association of Independent Agents & Brokers, where it held that a controversy is ripe for judicial resolution where the parties' rights and obligations can be determined "without awaiting the occurrence of some future contingency." 373 Mass. at 293. A dispute is "especially ripe" — to use the Court's framing — where one party has already acted on its disputed interpretation of the agreement or legal standard at issue, and the other party faces imminent or ongoing harm as a result. Id. In such circumstances, the court is not being asked to speculate about future events or to render an opinion on an abstract question; it is being asked to resolve a present, concrete conflict with real consequences.

Additional authorities reinforce these principles. In Lockwood v. Commissioner of Revenue, 379 Mass. 674, 677 (1980), the Supreme Judicial Court held that ripeness requires the dispute to have "taken shape" sufficiently that the court can render a judgment of practical utility. The Lockwood Court contrasted ripe disputes — where the parties' legal positions are fixed and the consequences of a declaration are concrete — with premature disputes, where future events might alter the legal landscape or moot the controversy entirely. Id. Here, the parties' positions are fixed, the commercial activity is ongoing, and no future event could moot the fundamental question of contract interpretation.

B. Application to This Matter

1. Fitness for Judicial Resolution

The dispute between Penterra and Vantage is eminently fit for judicial resolution. The core question — whether Exhibit A's enumeration of six New England states defines the exclusive outer boundary of Vantage's Territory under the EDA — is a pure question of contract interpretation. Massachusetts courts construe written contracts as a matter of law where the contract language is unambiguous. See Bank v. Thermo Elemental Inc., 451 Mass. 638, 648 (2008). The relevant provisions — Section 2.1, Section 2.3, Exhibit A, Section 13.1, and Section 14.8 — are contained in a fully executed written agreement that is available for the court's review.

The subsidiary questions presented by the dispute are also primarily legal in nature. Vantage's claim that the January 12, 2018 Kapoor Email constitutes "prior written consent" under Section 2.3 or an amendment to the Territory under Section 13.1 raises the legal question of what constitutes a valid written modification or consent under the EDA, as informed by the integration clause in Section 14.8 and the written-amendment requirement in Section 13.1. While the Kapoor Email itself is a factual document that will need to be placed in evidence, the legal question of whether its contents satisfy the contractual prerequisites for consent or amendment is a question of law that the court is well-positioned to resolve. Similarly, any argument by Vantage that course of dealing or course of performance can override the written terms of the EDA raises a legal question that is fit for judicial resolution under established Massachusetts precedent regarding parol evidence and integration clauses.

No future contingency needs to occur before the court can resolve this dispute. Vantage has already been distributing Oncalaris® in the Tri-State Area since approximately September 14, 2020 — a period of more than six months at the time of filing. The contractual provisions at issue have been in effect since the EDA was executed on July 1, 2017. The Kapoor Email dates to January 12, 2018. All relevant events have occurred; the court is not being asked to speculate about what might happen in the future but rather to interpret a written contract in light of events that have already taken place. This is precisely the type of dispute that courts are equipped to resolve through declaratory judgment.

2. Hardship to the Parties of Withholding Review

The hardship to Penterra of withholding judicial review is substantial and ongoing.

Interference with Penterra's commercial strategy. Vantage's unauthorized Tri-State distribution directly interferes with Penterra's ability to appoint Meridian National Distributors, Inc. — or any other distributor — in the Tri-State Area and Maryland. The Meridian term sheet, executed on February 15, 2021, contemplated a 90-day exclusivity period for negotiation of a definitive distribution agreement. That exclusivity period is now running, and Penterra cannot finalize the Meridian arrangement while Vantage continues to assert territorial rights in the same states. Penterra's broader commercial strategy for Oncalaris® — which generated approximately $412 million in fiscal year 2021 revenue, representing approximately 22% of Penterra's $1.87 billion consolidated revenue — depends on the orderly appointment of qualified distributors in key geographic markets. The Tri-State Area, which includes the major metropolitan markets of New York City, northern New Jersey, and the Philadelphia corridor, is among the most significant oncology markets in the United States. Penterra cannot afford to leave those markets in limbo while the territorial dispute festers.

Exposure to Vantage's threatened counterclaim. If Penterra proceeds to appoint Meridian — or any other distributor — in the Tri-State Area without first obtaining judicial resolution of the territorial dispute, Penterra faces exposure to Vantage's threatened $35 million counterclaim for breach of contract and tortious interference. This exposure creates a classic "Hobson's choice": Penterra can either (a) proceed with the Meridian arrangement and risk a $35 million counterclaim, or (b) refrain from appointing a new distributor in the Tri-State Area and suffer the ongoing commercial harm of leaving those markets underserved or served exclusively by Vantage on terms Penterra disputes. Declaratory relief is precisely the mechanism designed to resolve such dilemmas by providing judicial clarity before either party is forced to act at its peril.

Vantage's own interest in clarity. Although the hardship analysis focuses primarily on the party seeking declaratory relief, it is worth noting that Vantage also has an interest in judicial resolution. Vantage has invested in Tri-State sales infrastructure, has established customer relationships with hospitals and oncology clinics across three states, and has generated $6.4 million in revenues in the disputed territory. If Vantage's interpretation of the EDA is ultimately rejected, Vantage faces potential liability for breach of the territorial limitations in Section 2.3, as well as potential disgorgement or damages claims related to its unauthorized distribution. The sooner the territorial question is resolved, the sooner Vantage can adjust its commercial conduct accordingly.

Delay would compound uncertainty and damages. Every month that the territorial dispute remains unresolved, Vantage continues to distribute Oncalaris® in the Tri-State Area, potentially increasing its own exposure and Penterra's claimed damages. At the same time, Penterra's inability to appoint a competing distributor in those states means lost sales, lost market share, and lost momentum for a product that faces increasing competitive pressure from biosimilar entrants. Delay would serve no party's interest and would only increase the financial stakes on both sides.

3. Conclusion on Ripeness

For all of the foregoing reasons, the controversy between Penterra and Vantage is ripe for adjudication. The dispute presents a predominantly legal question of contract interpretation that is fit for judicial resolution based on the existing contractual instruments and undisputed facts. Withholding review would cause ongoing and escalating commercial hardship to Penterra, and delay would serve neither party's interest. The ripeness requirement is satisfied.

V. Standing

A. Legal Standard

Under Massachusetts law, a party seeking declaratory relief must demonstrate a personal stake in the outcome of the controversy — that is, the party must show that its legal rights, duties, or status will be directly affected by the declaration sought. G.L. c. 231A, § 2 provides that "any person whose rights, status or other legal relations are affected by" a contract or other instrument in writing may obtain a declaration of rights thereunder.

The Supreme Judicial Court has articulated the standing requirement for declaratory-judgment actions in terms familiar from the broader standing jurisprudence. In Enos v. Secretary of Environmental Affairs, 432 Mass. 132, 135 (2000), the Court held that a party seeking declaratory relief must demonstrate a "direct, substantial and adverse" interest in the matter. The interest must be more than a generalized grievance or an abstract concern; it must be a concrete, particularized interest in the outcome of the litigation that is personal to the plaintiff.

In the context of contract disputes, the standing requirement is typically straightforward: a party to the contract has standing to seek a declaratory judgment construing the contract's terms because its rights and obligations under the contract are directly at stake. See G.L. c. 231A, § 2; see also Northpoint Casualty Group Life Ins. Co. v. Haworth, 300 U.S. 227, 240–41 (1937) (analogous federal declaratory-judgment standing principles). Where the plaintiff is a signatory to the agreement in question and the declaration sought will determine the scope of the plaintiff's rights and obligations under that agreement, standing is essentially beyond dispute.

B. Application to This Matter

Penterra's standing to seek declaratory relief is clear and should not be subject to any serious challenge.

Penterra is a party to the EDA. Penterra is the "Supplier" under the EDA, and it was Penterra that granted the exclusive distribution rights at issue in Section 2.1. As a signatory to the agreement, Penterra's rights, duties, and obligations under the EDA are directly affected by the interpretation of the Territory. If the Territory is limited to the six New England states identified in Exhibit A — as Penterra contends — then Penterra retains the right to appoint other distributors in the Tri-State Area and Vantage's distribution in those states is unauthorized. If the Territory extends to the Tri-State Area — as Vantage contends — then Penterra is bound by the exclusivity grant and may not appoint a competing distributor in those states without Vantage's consent. The scope of the Territory thus directly determines the extent of Penterra's commercial freedom with respect to one of its most significant pharmaceutical products.

Penterra's commercial operations are materially affected. As discussed at length above, Penterra cannot finalize the Meridian arrangement (term sheet dated February 15, 2021) without judicial resolution of the territorial dispute. Penterra's ability to execute its Tri-State distribution strategy — and, more broadly, its ability to maximize the commercial potential of Oncalaris® in the northeastern United States — depends on the outcome of this action.

Penterra faces substantial financial exposure. Vantage has threatened a $35 million counterclaim for breach of contract and tortious interference, which will crystallize based on the interpretation of the Territory. Penterra's exposure to this counterclaim represents a concrete and substantial adverse interest in the declaration sought. If the Territory is properly limited to the six New England states, Vantage's counterclaim has no contractual basis; if the Territory extends to the Tri-State Area, Penterra's actions in pursuing the Meridian arrangement could be found to constitute a breach.

Conclusion on standing. Penterra plainly has standing as a contracting party with a direct, substantial, and adverse interest in the declaration sought. No colorable challenge to Penterra's standing exists.

VI. Potential Challenges by Vantage and Responses

This section anticipates the threshold challenges that Vantage may raise in opposition to Penterra's declaratory-judgment action and provides recommended responses for each.

A. Argument That Declaratory Judgment Is Inappropriate Because Coercive Relief Is Available

Anticipated argument. Vantage may argue that Penterra should have brought a traditional breach-of-contract action seeking damages, rather than a declaratory-judgment action, and that the availability of coercive relief renders declaratory relief inappropriate.

Response. This argument is foreclosed by the plain text of G.L. c. 231A, § 1, which expressly permits declaratory relief "whether or not further relief is or could be claimed." The Massachusetts Legislature specifically anticipated situations in which a party might seek declaratory relief even though an action for damages or injunctive relief was available, and it made clear that the availability of such alternative remedies does not preclude declaratory relief. The statute reflects a considered policy judgment that declaratory relief serves an independent purpose — providing prospective clarity on the parties' rights and obligations — that coercive remedies do not necessarily serve.

Massachusetts courts have consistently applied this principle. In Shapiro v. Sutherland, 64 Mass. App. Ct. 27, 36 (2005), the Appeals Court observed that declaratory relief is particularly well-suited to resolving contract-construction disputes where the parties' primary need is for clarity regarding their respective rights and obligations, rather than for retrospective damages. Numerous other Massachusetts decisions have entertained declaratory-judgment actions in contexts where breach-of-contract claims were available, and none has held that the availability of coercive relief standing alone is a sufficient basis to dismiss a declaratory-judgment action.

Moreover, Penterra's primary objective in this action is prospective clarity. Penterra needs to know, going forward, whether it may appoint Meridian — or another distributor — in the Tri-State Area without incurring liability to Vantage. A breach-of-contract action focused on Vantage's past conduct would not necessarily provide this prospective clarity, at least not as directly and efficiently as a declaratory judgment construing the scope of the Territory. While Penterra may ultimately pursue damages as well (and has reserved the right to seek consequential damages in the prayer for relief of its complaint), the primary purpose of the action is to obtain a binding judicial determination of the parties' rights under the EDA. This is precisely what declaratory relief is designed to accomplish.

B. Argument That the Dispute Is Not Ripe Because the EDA Has Not Yet Expired

Anticipated argument. The EDA's initial five-year term commenced on July 1, 2017, and expires on June 30, 2022. The agreement provides for two successive one-year auto-renewal options, which renew automatically unless either party provides 180 days' written notice of non-renewal. Vantage may argue that the territorial dispute can be resolved upon non-renewal of the EDA — that is, if Penterra simply declines to renew the agreement, the question of Vantage's territorial rights becomes moot, and there is no need for declaratory relief.

Response. This argument fails for multiple reasons.

First, the dispute is ripe now because Vantage is actively distributing Oncalaris® in the Tri-State Area, generating millions of dollars in revenue, and the parties have staked out irreconcilable legal positions on the interpretation of the EDA. The territorial dispute does not depend on the expiration or renewal of the EDA; it concerns the scope of the exclusivity grant during the term of the agreement. Even if Penterra were to decline to renew the EDA, the dispute over Vantage's past conduct — including the $6.4 million in Tri-State revenues and the question of whether those revenues were authorized — would not be resolved. The parties would still need judicial resolution of the contractual question in order to determine their respective rights and liabilities with respect to the events that occurred during the EDA's term.

Second, waiting for the EDA to expire would not resolve the existing dispute over Vantage's past and ongoing unauthorized conduct. To the contrary, it would only increase the potential damages on both sides. Every additional month that Vantage distributes in the Tri-State Area without authorization increases Penterra's potential damages claim and, conversely, increases the amount of Vantage's counterclaim if its interpretation prevails. Delay would exacerbate, not resolve, the controversy.

Third, Penterra cannot afford to wait. As discussed above, the Meridian term sheet includes a 90-day exclusivity period, and Penterra needs to make real-time commercial decisions about its distribution strategy in the Tri-State Area. Forcing Penterra to wait until June 2022 (or later, if the EDA auto-renews) before obtaining judicial resolution would inflict severe commercial harm on Penterra and would serve no legitimate judicial interest.

Fourth, the ripeness doctrine does not require parties to wait until a contract expires before seeking a declaratory judgment construing its terms. The whole point of declaratory relief is to resolve uncertainty during the operative period of the contract, so that the parties can conform their conduct to their actual legal obligations. See G.L. c. 231A, § 1 (permitting declarations "either before or after a breach or violation" of the relevant legal obligation).

C. Argument That the Business Litigation Session Lacks Jurisdiction

Anticipated argument. Vantage may raise a jurisdictional challenge to the Business Litigation Session of the Suffolk County Superior Court.

Response. Any such challenge would be meritless. The EDA's Section 14.5 provides for exclusive jurisdiction in the "state or federal courts located in the Commonwealth of Massachusetts." The Business Litigation Session of the Superior Court in Suffolk County is a state court located in Massachusetts, clearly within the scope of this forum-selection clause. Massachusetts courts routinely enforce forum-selection clauses of this type, and the Business Litigation Session is the appropriate venue for complex commercial disputes of this nature.

Moreover, Vantage is a Massachusetts limited liability company with its principal office at 75 Cabot Road, Suite 310, Medford, Massachusetts 02155. Vantage is thus subject to general jurisdiction in Massachusetts under G.L. c. 223A. Penterra maintains a registered agent in Massachusetts — CT Statutory Agent Services at 155 Federal Street, Suite 700, Boston, Massachusetts 02110 — and has consented to jurisdiction through the forum-selection clause. No jurisdictional challenge should succeed.

Additionally, Suffolk County is a proper venue because both Calderwood & Harkness LLP (1 Federal Street, 35th Floor, Boston, Massachusetts 02110) and Hargrove, Sinclair & Polk LLP (200 Ashbury Asset Advisors, Suite 1800, Boston, Massachusetts 02109) maintain offices in Suffolk County, and the forum-selection clause is most naturally read as contemplating litigation in Suffolk County, where the principal business courts of the Commonwealth are located.

D. Argument That the Matter Should Be Resolved in Arbitration or Another Forum

Anticipated argument. Vantage may argue that the dispute should be submitted to arbitration or resolved in another forum.

Response. The EDA does not contain an arbitration clause. Section 14.5 provides exclusively for litigation in the "state or federal courts located in the Commonwealth of Massachusetts." No competing forum exists, and Vantage has no basis for compelling arbitration or seeking transfer to another forum.

In the absence of an arbitration clause, Massachusetts courts will not compel arbitration of a contract dispute. See Plymouth-Carver Reg'l Sch. Dist. v. J. Farmer & Co., 407 Mass. 1006, 1007 (1990). The parties negotiated a specific dispute-resolution mechanism — litigation in Massachusetts courts — and that mechanism governs.

VII. Governing Law Considerations

Section 14.2 of the EDA provides that the agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, without regard to the principles of conflicts of law thereof. This choice-of-law clause is enforceable under Massachusetts law, see Restatement (Second) of Conflict of Laws § 187 (1971) (widely followed in Massachusetts), and its implications are significant for several aspects of this dispute.

First, the choice-of-law clause means that Massachusetts substantive law governs the interpretation of the EDA, including the interpretation of the Territory as defined in Section 2.1 and Exhibit A. Massachusetts follows the objective theory of contract interpretation, giving words their ordinary meaning and construing the contract as a whole. See Bank v. Thermo Elemental Inc., 451 Mass. 638, 648 (2008). Where the contract language is unambiguous, the court will enforce it according to its terms, without resort to extrinsic evidence. Id.

Second, Massachusetts law on written-modification clauses is favorable to Penterra's position. In Cambridge Biotech Corp. v. Pasteur Falveris Diagnostics, 433 Mass. 122 (2000), the Supreme Judicial Court held that written-modification clauses are generally enforceable and operate to bar implied oral modifications. This principle is directly relevant to Vantage's claim that the January 12, 2018 Kapoor Email constituted either "prior written consent" under Section 2.3 or an amendment to the Territory under Section 13.1. If the Kapoor Email does not satisfy the formalities required by the written-amendment clause — which requires a "written instrument signed by both parties" — then it cannot serve as either consent or an amendment, regardless of whatever informal representations may have been made. This point will be developed in full in a separate research memorandum on written-modification clauses and course of dealing under Massachusetts law, which is forthcoming.

Third, the choice-of-law clause eliminates any argument by Vantage that the law of New York, New Jersey, or Pennsylvania should apply to the territorial dispute. Vantage might otherwise have argued that because the disputed distribution activity took place in those states, the law of those states should govern the interpretation of the territorial provisions. The express choice of Massachusetts law forecloses this argument. This is particularly important because the law of some other jurisdictions may be less favorable to Penterra's position on the enforceability of written-modification clauses or the admissibility of course-of-dealing evidence.

Fourth, the "without regard to conflicts of law" language in Section 14.2 means that even if a Massachusetts conflict-of-laws analysis would otherwise point to the law of another state, Massachusetts law applies. This is a standard provision in sophisticated commercial agreements and reflects the parties' shared intention that the law of a single jurisdiction — the Commonwealth of Massachusetts — govern all disputes arising under the EDA.

VIII. Procedural Considerations

A. Venue

The complaint was filed in Suffolk County, Business Litigation Session, consistent with both Section 14.5 of the EDA and the practical considerations of the parties. Calderwood & Harkness LLP maintains its office at 1 Federal Street, 35th Floor, Boston, Massachusetts 02110, and Vantage's counsel at Hargrove, Sinclair & Polk LLP is located at 200 Ashbury Asset Advisors, Suite 1800, Boston, Massachusetts 02109. Both firms are located in Suffolk County, and the Business Litigation Session at the Suffolk County Superior Court is the designated venue for complex commercial litigation in the Commonwealth.

The case has been assigned to the Honorable Diane L. Costigan, Justice of the Superior Court. Judge Costigan has extensive experience with complex commercial matters in the Business Litigation Session and is well-versed in declaratory-judgment practice under G.L. c. 231A. The litigation team should be aware that Judge Costigan is known for adhering closely to scheduling orders and for expecting thorough briefing on dispositive motions, including comprehensive citation to the governing contractual provisions and applicable case law.

B. Counterclaims

On or about May 10, 2021, Vantage filed its Answer and Counterclaims, asserting the following three counterclaims against Penterra:

1. Breach of Contract. Vantage alleges that Penterra breached the EDA by threatening to appoint a competing distributor (Meridian) in the Tri-State Area, which Vantage claims is part of its exclusive Territory.

2. Breach of Implied Covenant of Good Faith and Fair Dealing. Vantage alleges that Penterra acted in bad faith by issuing the March 8, 2021 cease-and-desist letter and by pursuing the Meridian arrangement, allegedly in an effort to undermine Vantage's contractual rights.

3. Promissory Estoppel. Vantage alleges that it relied on representations made by Steven Kapoor (including but not limited to the January 12, 2018 email) to invest in Tri-State sales infrastructure and customer relationships, and that Penterra should be estopped from denying Vantage's territorial rights in those states.

Vantage seeks damages of $35 million across these counterclaims. Penterra filed its Answer to Counterclaims on June 4, 2021, denying all material allegations and raising affirmative defenses including the written-amendment requirement, the integration clause, failure to mitigate, and unclean hands.

The existence of Vantage's counterclaims does not defeat the declaratory-judgment action. To the contrary, the counterclaims confirm the existence of an actual controversy between the parties and underscore the need for judicial resolution. The declaratory-judgment action and the counterclaims will be resolved in the same proceeding, and the court's interpretation of the EDA's territorial provisions will be dispositive (or at least highly relevant) to both the declaratory claim and the counterclaims.

C. Standard of Review on Any Dispositive Motion

Cross-motions for summary judgment are well-suited to declaratory-judgment actions involving contract interpretation where the relevant documents are undisputed and the dispute turns on questions of law. See Mass. R. Civ. P. 56(c); Lenz v. CNA Assurance Co., 42 Mass. App. Ct. 260, 261 (1997) (summary judgment appropriate in declaratory-judgment action involving contract interpretation).

The court will construe the EDA's terms as a matter of law if the contract is unambiguous, applying standard principles of Massachusetts contract interpretation. Under these principles, the court gives words their ordinary meaning, construes the contract as a whole, and gives effect to all provisions so that no provision is rendered superfluous. See Bank v. Thermo Elemental Inc., 451 Mass. 638, 648 (2008). If the court finds the contract language ambiguous, extrinsic evidence — including the Kapoor Email, course of dealing, and course of performance — may be considered to resolve the ambiguity. See Robert Indus., Inc. v. Spence, 362 Mass. 751, 754 (1973).

The litigation team should begin preparing for summary judgment at an early stage, focusing on assembling the contractual documents (the EDA, Exhibit A, and any relevant amendments or correspondence) and developing the legal arguments for and against ambiguity.

IX. Conclusion and Recommendation

Based on the foregoing analysis, Penterra's declaratory-judgment action under G.L. c. 231A satisfies all threshold requirements for declaratory relief:

Actual Controversy. The parties hold irreconcilable positions on the scope of the Territory defined in the EDA, and those positions are backed by concrete actions and substantial financial stakes. Vantage has generated approximately $6.4 million in Tri-State revenues since September 2020. Penterra has issued a formal cease-and-desist demand. Vantage has threatened a $35 million counterclaim. The Meridian term sheet remains stalled. The controversy is actual, definite, and concrete.

Ripeness. The dispute is fit for judicial resolution because it presents a predominantly legal question of contract interpretation that can be resolved on the face of the EDA and the undisputed surrounding circumstances. No future contingency needs to occur; Vantage has already been distributing in the Tri-State Area for more than six months. Withholding review would cause ongoing and escalating commercial hardship to Penterra, including interference with the Meridian arrangement, exposure to Vantage's $35 million counterclaim, and uncertainty regarding Penterra's distribution strategy for a product that represents 22% of its consolidated revenue.

Standing. Penterra is a direct party to the EDA with a substantial and adverse interest in the scope of the Territory grant. Its legal rights, commercial operations, and financial exposure are all directly affected by the interpretation of the contractual provisions at issue.

Jurisdiction and Venue. The action is properly filed in the Business Litigation Session, Suffolk County, consistent with Section 14.5 of the EDA, Vantage's Massachusetts domicile, and Massachusetts procedural requirements. No jurisdictional or venue challenge should succeed.

Recommendations. Based on the foregoing, I recommend the following:

1. The litigation team should proceed to vigorously defend the ripeness and propriety of declaratory relief in anticipation of any threshold challenge by Vantage. If Vantage files a motion to dismiss under Mass. R. Civ. P. 12(b)(1) or 12(b)(6), or a motion for judgment on the pleadings, the team should be prepared to brief the issues identified in this memorandum, with particular emphasis on the actual-controversy and ripeness analyses.

2. The team should prepare for discovery, including the identification and collection of key documents (the EDA and all exhibits, the Kapoor Email of January 12, 2018, the March 8, 2021 cease-and-desist letter, the March 22, 2021 response from Hargrove, Sinclair & Polk LLP, the Meridian term sheet, and Penterra's internal correspondence regarding the Tri-State distribution dispute).

3. The team should begin developing the record for eventual cross-motions for summary judgment on the merits, focusing on the contract-interpretation arguments and the enforceability of the written-amendment clause.

4. A separate research memorandum on written-modification clauses and course of dealing under Massachusetts law is forthcoming. That memorandum will address the substance of Vantage's anticipated defense — including the claim that the Kapoor Email constitutes "prior written consent" or an amendment to the Territory — in the context of Cambridge Biotech Corp. v. Pasteur Falveris Diagnostics, 433 Mass. 122 (2000), and related authorities.

I am available to discuss this memorandum and its conclusions at the team's convenience.

X. Table of Authorities

Statutes

Cases

Other Authorities

Prepared by Patrick Gallagher, Working Associate, Calderwood & Harkness LLP. This memorandum is a privileged and confidential attorney work product. Distribution is restricted to the individuals identified in the header.

Authority	Citation
Massachusetts Declaratory Judgment Statute	G.L. c. 231A, §§ 1–3
Massachusetts Long-Arm Statute	G.L. c. 223A
Case	Citation	Relevance
Bunker Hill Distrib., Inc. v. District Attorney for the Suffolk Dist.	376 Mass. 142 (1978)	"Actual controversy" standard; definite and concrete issues; liberal construction of c. 231A
Lockwood v. Commissioner of Revenue	379 Mass. 674 (1980)	Ripeness; advisory-opinion prohibition
Massachusetts Ass'n of Indep. Agents & Brokers, Inc. v. Commissioner of Ins.	373 Mass. 290 (1977)	Ripeness two-pronged inquiry; resolution without awaiting future contingency
Enos v. Secretary of Envtl. Affairs	432 Mass. 132 (2000)	Standing; "direct, substantial and adverse" interest
Cambridge Biotech Corp. v. Pasteur Falveris Diagnostics	433 Mass. 122 (2000)	Written-modification clauses; enforceability (full analysis reserved for separate memorandum)
Bank v. Thermo Elemental Inc.	451 Mass. 638 (2008)	Contract interpretation; objective theory; unambiguous contracts construed as matter of law
Morrissey v. New England Deaconess Ass'n	358 Mass. 764 (1971)	Liberal construction of declaratory-judgment statute
Boston Safe Deposit & Trust Co. v. Stratton	259 Mass. 465 (1927)	Court discretion under c. 231A
Shapiro v. Sutherland	64 Mass. App. Ct. 27 (2005)	Declaratory relief appropriate for contract-construction disputes
Boston v. Keene Corp.	406 Mass. 301 (1989)	"Actual controversy" requirement
Robert Indus., Inc. v. Spence	362 Mass. 751 (1973)	Extrinsic evidence for ambiguous contracts
Lenz v. CNA Assurance Co.	42 Mass. App. Ct. 260 (1997)	Summary judgment in declaratory-judgment actions
Plymouth-Carver Reg'l Sch. Dist. v. J. Farmer & Co.	407 Mass. 1006 (1990)	Arbitration; court will not compel absent agreement
Northpoint Casualty Group Life Ins. Co. v. Haworth	300 U.S. 227 (1937)	Declaratory-judgment standing principles (federal analogy)
Sullivan v. Chief Justice for Admin. & Mgmt. of the Trial Court	448 Mass. 15 (2006)	Declaratory relief to construe contractual instruments
Authority	Citation
Restatement (Second) of Conflict of Laws	§ 187 (1971)
Massachusetts Rules of Civil Procedure	Rule 12(b)(1); Rule 12(b)(6); Rule 56(c)

PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT This memorandum is protected by the attorney-client privilege and the work-product doctrine. It is intended solely for internal use by attorneys and staff of Calderwood & Harkness LLP working on the above-referenced matter. Do not distribute, copy, or disclose this memorandum or any portion thereof without prior authorization from the Responsible Partner.
CALDERWOOD & HARKNESS LLP 1 Federal Street, 35th Floor Boston, Massachusetts 02110
INTERNAL MEMORANDUM
TO: Linda Osei, Responsible Partner Priya Anand, Billing Partner Hannah Brinkley, Lead Associate
FROM: Patrick Gallagher, Working Associate
DATE: April 5, 2021
RE: Massachusetts Declaratory Judgment Standards and Ripeness — Penterra Pharmaceuticals Corp. v. Vantage Medical Distribution, LLC
Matter No.: 1018-00007
Docket No.: 2184-CV-01537-BLS (MA Superior Court, Business Litigation Session, Suffolk County)
Right-click to update Table of Contents
I. Introduction and Purpose of Memorandum
This memorandum analyzes whether the declaratory-judgment action filed by Penterra Pharmaceuticals Corp. ("Penterra" or "PPC") on April 12, 2021, in the Superior Court of Massachusetts, Business Litigation Session, Suffolk County, satisfies the statutory requirements for declaratory relief under Massachusetts General Laws chapter 231A, §§ 1–3. The purpose of this memorandum is to provide the litigation team with a comprehensive assessment of the threshold legal standards governing declaratory relief in Massachusetts and to evaluate our client's position in the event Vantage Medical Distribution, LLC ("Vantage") raises a preliminary challenge to the propriety of the declaratory-judgment action on grounds of ripeness, standing, or the availability of alternative remedies.
Penterra's complaint seeks a judicial declaration that Vantage has no exclusive distribution rights beyond the six New England states — Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont — as defined in Exhibit A to the Exclusive Distribution Agreement dated July 1, 2017 (the "EDA"). The complaint further seeks a declaration that Vantage's distribution of Oncalaris® (pegvisomant-axel) in New York, New Jersey, and Pennsylvania (collectively, the "Tri-State Area") is unauthorized under the EDA and constitutes a material breach of Vantage's obligations thereunder.
This memorandum addresses five principal subjects: (1) the statutory framework for declaratory judgment in Massachusetts under G.L. c. 231A; (2) the "actual controversy" requirement and its application to the facts of this matter; (3) the ripeness doctrine and its two-pronged inquiry under Massachusetts law; (4) Penterra's standing to seek declaratory relief as a party to the EDA; and (5) an analysis of the potential threshold challenges Vantage may raise, together with recommended responses.
Summary Conclusion: Based on the analysis below, it is my assessment that Penterra's declaratory-judgment claim is well-suited for declaratory relief and should survive any challenge by Vantage on jurisdictional, ripeness, or standing grounds. The dispute between the parties involves a concrete, definite, and presently existing controversy over the interpretation of a fully executed written contract, and the parties have taken irreconcilable positions supported by concrete commercial actions and substantial financial stakes. The litigation team should proceed with confidence in the procedural propriety of the action and prepare to defend the declaratory-judgment framework in any threshold motion practice.
II. Statutory Framework: G.L. c. 231A
A. Text of the Statute
Massachusetts General Laws chapter 231A provides the statutory basis for declaratory relief in the Commonwealth. The relevant provisions are as follows:
Section 1 provides, in pertinent part:
"The supreme judicial court, the superior court, the land court, and the probate courts, within their respective jurisdictions, may on appropriate proceedings make binding declarations of right, duty, status and other legal relations sought thereby, either before or after a breach or violation thereof, and such proceedings shall not be open to objection on the ground that a merely declaratory judgment or decree is sought thereby and such declaration, when made, shall have the force of a final judgment or decree and be reviewable as such . . . ."
G.L. c. 231A, § 1. This section establishes the authority of the Superior Court — the tribunal in which Penterra's action is pending — to render binding declarations of right. Critically, the statute permits such declarations "either before or after a breach or violation," which confirms that a party need not wait until a breach has occurred or damages have been sustained before seeking declaratory relief. This is directly relevant here, as Penterra seeks both prospective clarity (regarding its right to appoint other distributors in the Tri-State Area) and a declaration regarding past conduct (Vantage's allegedly unauthorized distribution since September 2020).
Section 1 further provides that declarations made under the statute "shall have the force of a final judgment or decree." This means that a declaratory judgment construing the EDA would be binding on both Penterra and Vantage, would be enforceable through contempt proceedings if necessary, and would be reviewable on appeal as a final judgment. The finality provision underscores the Legislature's intent that declaratory relief serve as a meaningful and self-sufficient remedy, not merely an advisory or precatory opinion.
Section 2 expands on the scope of declaratory relief available:
"Any person claiming a present legal or equitable right or title may maintain a petition or action in the appropriate court to determine the same, and the court may make a binding declaration of such right or title, whether or not any consequential relief is or could be claimed, including the determination of any question of construction or validity arising under any instrument, statute, ordinance, contract or franchise and a declaration of the rights, status or other legal relations of any party thereunder."
G.L. c. 231A, § 2. Section 2 is of particular importance to this matter because it expressly authorizes declarations of rights arising under a "contract" and permits the court to resolve "any question of construction" arising under that contract. The dispute between Penterra and Vantage is precisely the kind of contract-construction dispute that Section 2 was designed to address — the parties disagree about the proper interpretation of the Territory as defined in Section 2.1 and Exhibit A of the EDA, and the consequences of that disagreement are playing out in real commercial activity across the northeastern United States.
Equally important, Section 2 provides that declaratory relief may be granted "whether or not any consequential relief is or could be claimed." This language confirms that the availability of alternative remedies — such as a breach-of-contract action for damages — does not preclude declaratory relief. As discussed in Section VI.A below, Vantage may attempt to argue that Penterra should have pursued coercive relief instead; Section 2 forecloses that argument.
Section 3 addresses the court's discretion to decline declaratory relief:
"The court may refuse to make a binding declaration of right, duty, status or other legal relation where such declaration, if made, would not terminate the uncertainty or controversy giving rise to the proceeding."
G.L. c. 231A, § 3. Section 3 grants the court discretion to refuse declaratory relief where the declaration would not resolve the underlying controversy. This provision is a safeguard against piecemeal litigation and advisory opinions. In the present case, however, the declaration sought by Penterra would squarely resolve the central dispute — the scope of Vantage's Territory — and would provide both parties with the clarity needed to govern their commercial conduct going forward. A declaration that the Territory is limited to the six New England states enumerated in Exhibit A would terminate the controversy over whether Vantage has the right to distribute Oncalaris® in the Tri-State Area and would enable Penterra to proceed with the Meridian arrangement or other distribution partnerships in those states.
Finally, it is well established that G.L. c. 231A is remedial in nature and is to be liberally construed to settle and afford relief from uncertainty and insecurity with respect to rights, duties, status, and other legal relations. See Morrissey v. New England Deaconess Ass'n, 358 Mass. 764, 766 (1971); Bunker Hill Distrib., Inc. v. District Attorney for the Suffolk Dist., 376 Mass. 142, 144 (1978). Courts are instructed to resolve doubts about the availability of declaratory relief in favor of entertaining the action, consistent with the remedial purposes of the statute.
B. Scope and Discretion
Massachusetts courts have broad discretion under G.L. c. 231A to determine whether declaratory relief is appropriate in a given case. That discretion, however, is not unfettered. Where a genuine controversy exists between parties with adverse legal interests, and where the declaration sought would terminate the uncertainty giving rise to the proceeding, courts are expected to exercise their discretion in favor of granting relief. See Bunker Hill Distrib., 376 Mass. at 144–45; Boston Safe Deposit & Trust Co. v. Stratton, 259 Mass. 465, 470 (1927).
It is important to note that G.L. c. 231A does not itself create subject-matter jurisdiction. Rather, the statute provides a remedy — declaratory relief — that is available in courts of competent jurisdiction. Jurisdiction must exist independently, either through the general jurisdictional provisions applicable to the tribunal in question or through the parties' consent. In this case, jurisdiction in the Superior Court is well established on multiple independent grounds. First, Section 14.5 of the EDA provides that the parties consent to the exclusive jurisdiction of the "state or federal courts located in the Commonwealth of Massachusetts" for any disputes arising under the agreement. Second, Vantage is a Massachusetts limited liability company with its principal place of business at 75 Cabot Road, Suite 310, Medford, Massachusetts 02155, and is therefore subject to general jurisdiction in Massachusetts. Third, Penterra maintains a registered agent for service of process in Massachusetts through CT Statutory Agent Services at 155 Federal Street, Suite 700, Boston, Massachusetts 02110, and has consented to jurisdiction through the forum-selection clause. No jurisdictional deficiency exists.
The court may decline declaratory relief where another remedy is more appropriate, but Massachusetts courts exercise this discretion sparingly in cases involving genuine contract disputes. See Shapiro v. Sutherland, 64 Mass. App. Ct. 27, 36 (2005) (observing that declaratory relief is well-suited to resolving contract-construction disputes). Contract-interpretation cases present paradigmatic circumstances for declaratory relief: the relevant instruments are fixed, the parties' positions are defined, and the court can render a declaration that provides immediate and lasting clarity to both sides.
III. The "Actual Controversy" Requirement
A. Legal Standard
The central prerequisite for declaratory relief under G.L. c. 231A is the existence of an "actual controversy." The Supreme Judicial Court has consistently held that the statute does not authorize courts to render advisory opinions or to decide hypothetical questions; there must be a real and substantial dispute between parties with genuinely adverse legal interests. See Bunker Hill Distrib., Inc. v. District Attorney for the Suffolk Dist., 376 Mass. 142, 144–45 (1978); Boston v. Keene Corp., 406 Mass. 301, 304 (1989).
In Bunker Hill Distribution, the Supreme Judicial Court set forth the governing standard: the controversy must involve "definite and concrete" issues between "parties having adverse legal interests." 376 Mass. at 144–45. The Court further explained that the dispute must be "of sufficient immediacy and reality to warrant the issuance of a declaratory judgment." Id. This formulation requires something more than a theoretical disagreement or a speculative future conflict; the parties must be engaged in a present controversy with concrete stakes.
In Lockwood v. Commissioner of Revenue, 379 Mass. 674, 677 (1980), the Supreme Judicial Court elaborated on this standard, holding that the controversy must be "ripe" for judicial resolution and not merely advisory in nature. The Court in Lockwood emphasized that the actual-controversy requirement serves two related purposes: it prevents courts from issuing opinions on abstract questions of law, and it ensures that judicial resources are directed to disputes where a declaration will have practical consequences for the parties. Id. at 677–78.
Several additional principles inform the actual-controversy analysis. First, the action may be maintained even though the plaintiff could have sought coercive relief, such as damages for breach of contract. Declaratory judgment is an independent remedy available under G.L. c. 231A, § 2, "whether or not further relief is or could be claimed." The plaintiff is not required to demonstrate that declaratory relief is the only remedy available; it need only demonstrate that a genuine controversy exists and that declaratory relief would serve to resolve it. Second, Massachusetts courts regularly entertain declaratory-judgment actions to construe contracts, including exclusive distribution agreements, franchise agreements, licensing agreements, and other commercial instruments. See, e.g., Sullivan v. Chief Justice for Admin. & Mgmt. of the Trial Court, 448 Mass. 15, 22–23 (2006); Cambridge Biotech Corp. v. Pasteur Falveris Diagnostics, 433 Mass. 122 (2000) (addressing contract interpretation in declaratory-judgment posture).
The existence of a counterclaim by the defendant — far from defeating the declaratory-judgment action — typically confirms the existence of an actual controversy. Where both parties have staked out adverse positions and each claims affirmative rights under the contract, the controversy is, if anything, more sharply defined.
B. Application to This Matter
The dispute between Penterra and Vantage satisfies the "actual controversy" requirement in every respect. The controversy is actual, concrete, definite, and of sufficient immediacy and reality to warrant declaratory relief.
Vantage's commencement of Tri-State distribution. The controversy is not a matter of speculation or hypothetical planning. Vantage began shipping Oncalaris® to hospitals and oncology clinics in New York, New Jersey, and Pennsylvania on or about September 14, 2020. According to Penterra's internal commercial intelligence reports (provided to this firm as part of the initial client intake), Vantage generated approximately $6.4 million in Tri-State revenues through March 2021. These shipments were made to at least fourteen hospital systems and oncology practice groups across the three states, including major accounts at NewYork-Presbyterian Hospital, Harborline Industries, and the Hospital of the University of Pennsylvania. Vantage's Tri-State distribution activities are thus not prospective or contingent; they represent a substantial, ongoing course of commercial conduct that Penterra asserts is unauthorized under the EDA.
Penterra's cease-and-desist demand. On March 8, 2021, Penterra's General Counsel, Jennifer Chao, sent a formal cease-and-desist letter to Vantage CEO Donald R. Farnham, demanding that Vantage immediately cease distributing Oncalaris® outside the six New England states identified in Exhibit A to the EDA. The letter stated Penterra's position unequivocally: Vantage's Territory is limited to the six New England states, and any distribution outside that Territory constitutes a material breach of Section 2.3 of the EDA, which prohibits the Distributor from soliciting or delivering product outside the Territory without the prior written consent of the Supplier.
Vantage's adversarial response. On March 22, 2021, Vantage's outside counsel, Kenneth M. Rourke of Hargrove, Sinclair & Polk LLP, responded to Penterra's cease-and-desist letter with a detailed eleven-page letter asserting that Vantage possessed exclusive distribution rights in the Tri-State Area. Specifically, Mr. Rourke's letter contended that an email dated January 12, 2018, from Steven Kapoor, Penterra's Vice President of Commercial Operations, to Donald Farnham, constituted "prior written consent" under Section 2.3 of the EDA — or, alternatively, a written amendment to the Territory under Section 13.1 — authorizing Vantage to distribute Oncalaris® in the Tri-State Area. The letter further threatened that Vantage would pursue a breach-of-contract and tortious interference counterclaim seeking no less than $35 million in damages if Penterra appointed a competing distributor in those states. The March 22 letter left no doubt that the parties' positions are diametrically opposed.
The stalled Meridian arrangement. Penterra had executed a binding term sheet with Meridian National Distributors, Inc. on February 15, 2021, contemplating an exclusive distribution arrangement for Oncalaris® in New York, New Jersey, Pennsylvania, and Maryland. The Meridian term sheet, which was negotiated by Penterra's VP of Strategic Partnerships, included a 90-day exclusivity period for the negotiation of a definitive distribution agreement. However, the Meridian transaction has stalled as a direct consequence of Vantage's assertion of territorial rights in the Tri-State Area. Meridian's counsel has indicated that Meridian will not proceed to a definitive agreement until the territorial dispute with Vantage is resolved. The stalled Meridian arrangement represents a concrete, ongoing commercial harm to Penterra that can only be remedied through judicial clarification of the parties' rights under the EDA.
The contractual provisions in dispute. The parties have taken concrete, adverse positions on the interpretation of specific provisions of the EDA, including:
• Section 2.1 (Grant of Exclusive Territory): This section grants Vantage the exclusive right to distribute Oncalaris® within the "Territory" as defined in Exhibit A.
• Exhibit A (Territory Definition): Exhibit A identifies the Territory as the states of Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont — and no other states.
• Section 2.3 (Limitation on Solicitation/Delivery Outside the Territory): This section provides that the Distributor "shall not, directly or indirectly, solicit orders for, market, sell, or deliver the Products to any customer or end user located outside the Territory without the prior written consent of the Supplier."
• Section 13.1 (Written Amendment Requirement): This section provides that "no amendment, modification, or waiver of any provision of this Agreement shall be valid unless set forth in a written instrument signed by both parties."
• Section 14.8 (Integration Clause): This section provides that the EDA "constitutes the entire agreement of the parties with respect to the subject matter hereof and supersedes all prior agreements, negotiations, and understandings, whether oral or written."
Vantage's position rests on its claim that the January 12, 2018 Kapoor Email constituted either "prior written consent" under Section 2.3 or an amendment to the Territory under Section 13.1. Penterra disputes this characterization and contends that the Kapoor Email — which appears to have discussed the possibility of future expansion into the Tri-State Area — did not constitute either consent or an amendment. The integration clause in Section 14.8 and the written-amendment requirement in Section 13.1 further support Penterra's position. The substance of these arguments will be developed in a separate memorandum on written-modification clauses and course of dealing under Massachusetts law.
Financial stakes. The controversy is not hypothetical; real commercial activity and real money are at stake. Vantage has generated approximately $6.4 million in disputed Tri-State revenues since September 2020. Vantage has threatened a $35 million counterclaim. The Meridian distribution deal — which would open significant new markets for Oncalaris® in the Mid-Atlantic region — remains stalled. Oncalaris® generated approximately $412 million in fiscal year 2021 revenue, representing approximately 22% of Penterra's $1.87 billion consolidated revenue. The financial materiality of this dispute is beyond question.
In sum, the parties have taken definite, concrete, and irreconcilable positions on the interpretation of the EDA, and those positions are backed by substantial commercial activity and financial exposure. This is precisely the type of dispute that declaratory relief under G.L. c. 231A was designed to resolve.
IV. Ripeness
A. Legal Standard
The ripeness doctrine ensures that courts do not issue advisory opinions or decide disputes prematurely, before the issues are sufficiently crystallized for judicial resolution. Ripeness is closely related to the "actual controversy" requirement but focuses more specifically on the timing and maturity of the dispute.
Under Massachusetts law, the ripeness inquiry involves two prongs:
First, fitness for judicial resolution. The court asks whether the issue presented is primarily legal in nature or whether it requires further factual development before judicial resolution would be appropriate. Contract-interpretation disputes are typically fit for judicial resolution because they raise predominantly legal questions that can be resolved on the face of the contract and the undisputed surrounding circumstances. See Massachusetts Ass'n of Indep. Agents & Brokers, Inc. v. Commissioner of Ins., 373 Mass. 290, 293 (1977). Where the relevant contractual instruments are fully executed and available for the court's review, and where the parties' positions can be evaluated based on the language of those instruments, the dispute is fit for judicial resolution without the need for further factual development.
Second, hardship to the parties of withholding review. The court asks whether declining to review the dispute would cause concrete harm to one or both parties. Where a party faces ongoing commercial injury, uncertainty that impedes business decisions, or exposure to substantial legal liability, the hardship of withholding review weighs in favor of finding the dispute ripe. See id. at 293–94.
The Supreme Judicial Court addressed these principles in Massachusetts Association of Independent Agents & Brokers, where it held that a controversy is ripe for judicial resolution where the parties' rights and obligations can be determined "without awaiting the occurrence of some future contingency." 373 Mass. at 293. A dispute is "especially ripe" — to use the Court's framing — where one party has already acted on its disputed interpretation of the agreement or legal standard at issue, and the other party faces imminent or ongoing harm as a result. Id. In such circumstances, the court is not being asked to speculate about future events or to render an opinion on an abstract question; it is being asked to resolve a present, concrete conflict with real consequences.
Additional authorities reinforce these principles. In Lockwood v. Commissioner of Revenue, 379 Mass. 674, 677 (1980), the Supreme Judicial Court held that ripeness requires the dispute to have "taken shape" sufficiently that the court can render a judgment of practical utility. The Lockwood Court contrasted ripe disputes — where the parties' legal positions are fixed and the consequences of a declaration are concrete — with premature disputes, where future events might alter the legal landscape or moot the controversy entirely. Id. Here, the parties' positions are fixed, the commercial activity is ongoing, and no future event could moot the fundamental question of contract interpretation.
B. Application to This Matter
1. Fitness for Judicial Resolution
The dispute between Penterra and Vantage is eminently fit for judicial resolution. The core question — whether Exhibit A's enumeration of six New England states defines the exclusive outer boundary of Vantage's Territory under the EDA — is a pure question of contract interpretation. Massachusetts courts construe written contracts as a matter of law where the contract language is unambiguous. See Bank v. Thermo Elemental Inc., 451 Mass. 638, 648 (2008). The relevant provisions — Section 2.1, Section 2.3, Exhibit A, Section 13.1, and Section 14.8 — are contained in a fully executed written agreement that is available for the court's review.
The subsidiary questions presented by the dispute are also primarily legal in nature. Vantage's claim that the January 12, 2018 Kapoor Email constitutes "prior written consent" under Section 2.3 or an amendment to the Territory under Section 13.1 raises the legal question of what constitutes a valid written modification or consent under the EDA, as informed by the integration clause in Section 14.8 and the written-amendment requirement in Section 13.1. While the Kapoor Email itself is a factual document that will need to be placed in evidence, the legal question of whether its contents satisfy the contractual prerequisites for consent or amendment is a question of law that the court is well-positioned to resolve. Similarly, any argument by Vantage that course of dealing or course of performance can override the written terms of the EDA raises a legal question that is fit for judicial resolution under established Massachusetts precedent regarding parol evidence and integration clauses.
No future contingency needs to occur before the court can resolve this dispute. Vantage has already been distributing Oncalaris® in the Tri-State Area since approximately September 14, 2020 — a period of more than six months at the time of filing. The contractual provisions at issue have been in effect since the EDA was executed on July 1, 2017. The Kapoor Email dates to January 12, 2018. All relevant events have occurred; the court is not being asked to speculate about what might happen in the future but rather to interpret a written contract in light of events that have already taken place. This is precisely the type of dispute that courts are equipped to resolve through declaratory judgment.
2. Hardship to the Parties of Withholding Review
The hardship to Penterra of withholding judicial review is substantial and ongoing.
Interference with Penterra's commercial strategy. Vantage's unauthorized Tri-State distribution directly interferes with Penterra's ability to appoint Meridian National Distributors, Inc. — or any other distributor — in the Tri-State Area and Maryland. The Meridian term sheet, executed on February 15, 2021, contemplated a 90-day exclusivity period for negotiation of a definitive distribution agreement. That exclusivity period is now running, and Penterra cannot finalize the Meridian arrangement while Vantage continues to assert territorial rights in the same states. Penterra's broader commercial strategy for Oncalaris® — which generated approximately $412 million in fiscal year 2021 revenue, representing approximately 22% of Penterra's $1.87 billion consolidated revenue — depends on the orderly appointment of qualified distributors in key geographic markets. The Tri-State Area, which includes the major metropolitan markets of New York City, northern New Jersey, and the Philadelphia corridor, is among the most significant oncology markets in the United States. Penterra cannot afford to leave those markets in limbo while the territorial dispute festers.
Exposure to Vantage's threatened counterclaim. If Penterra proceeds to appoint Meridian — or any other distributor — in the Tri-State Area without first obtaining judicial resolution of the territorial dispute, Penterra faces exposure to Vantage's threatened $35 million counterclaim for breach of contract and tortious interference. This exposure creates a classic "Hobson's choice": Penterra can either (a) proceed with the Meridian arrangement and risk a $35 million counterclaim, or (b) refrain from appointing a new distributor in the Tri-State Area and suffer the ongoing commercial harm of leaving those markets underserved or served exclusively by Vantage on terms Penterra disputes. Declaratory relief is precisely the mechanism designed to resolve such dilemmas by providing judicial clarity before either party is forced to act at its peril.
Vantage's own interest in clarity. Although the hardship analysis focuses primarily on the party seeking declaratory relief, it is worth noting that Vantage also has an interest in judicial resolution. Vantage has invested in Tri-State sales infrastructure, has established customer relationships with hospitals and oncology clinics across three states, and has generated $6.4 million in revenues in the disputed territory. If Vantage's interpretation of the EDA is ultimately rejected, Vantage faces potential liability for breach of the territorial limitations in Section 2.3, as well as potential disgorgement or damages claims related to its unauthorized distribution. The sooner the territorial question is resolved, the sooner Vantage can adjust its commercial conduct accordingly.
Delay would compound uncertainty and damages. Every month that the territorial dispute remains unresolved, Vantage continues to distribute Oncalaris® in the Tri-State Area, potentially increasing its own exposure and Penterra's claimed damages. At the same time, Penterra's inability to appoint a competing distributor in those states means lost sales, lost market share, and lost momentum for a product that faces increasing competitive pressure from biosimilar entrants. Delay would serve no party's interest and would only increase the financial stakes on both sides.
3. Conclusion on Ripeness
For all of the foregoing reasons, the controversy between Penterra and Vantage is ripe for adjudication. The dispute presents a predominantly legal question of contract interpretation that is fit for judicial resolution based on the existing contractual instruments and undisputed facts. Withholding review would cause ongoing and escalating commercial hardship to Penterra, and delay would serve neither party's interest. The ripeness requirement is satisfied.
V. Standing
A. Legal Standard
Under Massachusetts law, a party seeking declaratory relief must demonstrate a personal stake in the outcome of the controversy — that is, the party must show that its legal rights, duties, or status will be directly affected by the declaration sought. G.L. c. 231A, § 2 provides that "any person whose rights, status or other legal relations are affected by" a contract or other instrument in writing may obtain a declaration of rights thereunder.
The Supreme Judicial Court has articulated the standing requirement for declaratory-judgment actions in terms familiar from the broader standing jurisprudence. In Enos v. Secretary of Environmental Affairs, 432 Mass. 132, 135 (2000), the Court held that a party seeking declaratory relief must demonstrate a "direct, substantial and adverse" interest in the matter. The interest must be more than a generalized grievance or an abstract concern; it must be a concrete, particularized interest in the outcome of the litigation that is personal to the plaintiff.
In the context of contract disputes, the standing requirement is typically straightforward: a party to the contract has standing to seek a declaratory judgment construing the contract's terms because its rights and obligations under the contract are directly at stake. See G.L. c. 231A, § 2; see also Northpoint Casualty Group Life Ins. Co. v. Haworth, 300 U.S. 227, 240–41 (1937) (analogous federal declaratory-judgment standing principles). Where the plaintiff is a signatory to the agreement in question and the declaration sought will determine the scope of the plaintiff's rights and obligations under that agreement, standing is essentially beyond dispute.
B. Application to This Matter
Penterra's standing to seek declaratory relief is clear and should not be subject to any serious challenge.
Penterra is a party to the EDA. Penterra is the "Supplier" under the EDA, and it was Penterra that granted the exclusive distribution rights at issue in Section 2.1. As a signatory to the agreement, Penterra's rights, duties, and obligations under the EDA are directly affected by the interpretation of the Territory. If the Territory is limited to the six New England states identified in Exhibit A — as Penterra contends — then Penterra retains the right to appoint other distributors in the Tri-State Area and Vantage's distribution in those states is unauthorized. If the Territory extends to the Tri-State Area — as Vantage contends — then Penterra is bound by the exclusivity grant and may not appoint a competing distributor in those states without Vantage's consent. The scope of the Territory thus directly determines the extent of Penterra's commercial freedom with respect to one of its most significant pharmaceutical products.
Penterra's commercial operations are materially affected. As discussed at length above, Penterra cannot finalize the Meridian arrangement (term sheet dated February 15, 2021) without judicial resolution of the territorial dispute. Penterra's ability to execute its Tri-State distribution strategy — and, more broadly, its ability to maximize the commercial potential of Oncalaris® in the northeastern United States — depends on the outcome of this action.
Penterra faces substantial financial exposure. Vantage has threatened a $35 million counterclaim for breach of contract and tortious interference, which will crystallize based on the interpretation of the Territory. Penterra's exposure to this counterclaim represents a concrete and substantial adverse interest in the declaration sought. If the Territory is properly limited to the six New England states, Vantage's counterclaim has no contractual basis; if the Territory extends to the Tri-State Area, Penterra's actions in pursuing the Meridian arrangement could be found to constitute a breach.
Conclusion on standing. Penterra plainly has standing as a contracting party with a direct, substantial, and adverse interest in the declaration sought. No colorable challenge to Penterra's standing exists.
VI. Potential Challenges by Vantage and Responses
This section anticipates the threshold challenges that Vantage may raise in opposition to Penterra's declaratory-judgment action and provides recommended responses for each.
A. Argument That Declaratory Judgment Is Inappropriate Because Coercive Relief Is Available
Anticipated argument. Vantage may argue that Penterra should have brought a traditional breach-of-contract action seeking damages, rather than a declaratory-judgment action, and that the availability of coercive relief renders declaratory relief inappropriate.
Response. This argument is foreclosed by the plain text of G.L. c. 231A, § 1, which expressly permits declaratory relief "whether or not further relief is or could be claimed." The Massachusetts Legislature specifically anticipated situations in which a party might seek declaratory relief even though an action for damages or injunctive relief was available, and it made clear that the availability of such alternative remedies does not preclude declaratory relief. The statute reflects a considered policy judgment that declaratory relief serves an independent purpose — providing prospective clarity on the parties' rights and obligations — that coercive remedies do not necessarily serve.
Massachusetts courts have consistently applied this principle. In Shapiro v. Sutherland, 64 Mass. App. Ct. 27, 36 (2005), the Appeals Court observed that declaratory relief is particularly well-suited to resolving contract-construction disputes where the parties' primary need is for clarity regarding their respective rights and obligations, rather than for retrospective damages. Numerous other Massachusetts decisions have entertained declaratory-judgment actions in contexts where breach-of-contract claims were available, and none has held that the availability of coercive relief standing alone is a sufficient basis to dismiss a declaratory-judgment action.
Moreover, Penterra's primary objective in this action is prospective clarity. Penterra needs to know, going forward, whether it may appoint Meridian — or another distributor — in the Tri-State Area without incurring liability to Vantage. A breach-of-contract action focused on Vantage's past conduct would not necessarily provide this prospective clarity, at least not as directly and efficiently as a declaratory judgment construing the scope of the Territory. While Penterra may ultimately pursue damages as well (and has reserved the right to seek consequential damages in the prayer for relief of its complaint), the primary purpose of the action is to obtain a binding judicial determination of the parties' rights under the EDA. This is precisely what declaratory relief is designed to accomplish.
B. Argument That the Dispute Is Not Ripe Because the EDA Has Not Yet Expired
Anticipated argument. The EDA's initial five-year term commenced on July 1, 2017, and expires on June 30, 2022. The agreement provides for two successive one-year auto-renewal options, which renew automatically unless either party provides 180 days' written notice of non-renewal. Vantage may argue that the territorial dispute can be resolved upon non-renewal of the EDA — that is, if Penterra simply declines to renew the agreement, the question of Vantage's territorial rights becomes moot, and there is no need for declaratory relief.
Response. This argument fails for multiple reasons.
First, the dispute is ripe now because Vantage is actively distributing Oncalaris® in the Tri-State Area, generating millions of dollars in revenue, and the parties have staked out irreconcilable legal positions on the interpretation of the EDA. The territorial dispute does not depend on the expiration or renewal of the EDA; it concerns the scope of the exclusivity grant during the term of the agreement. Even if Penterra were to decline to renew the EDA, the dispute over Vantage's past conduct — including the $6.4 million in Tri-State revenues and the question of whether those revenues were authorized — would not be resolved. The parties would still need judicial resolution of the contractual question in order to determine their respective rights and liabilities with respect to the events that occurred during the EDA's term.
Second, waiting for the EDA to expire would not resolve the existing dispute over Vantage's past and ongoing unauthorized conduct. To the contrary, it would only increase the potential damages on both sides. Every additional month that Vantage distributes in the Tri-State Area without authorization increases Penterra's potential damages claim and, conversely, increases the amount of Vantage's counterclaim if its interpretation prevails. Delay would exacerbate, not resolve, the controversy.
Third, Penterra cannot afford to wait. As discussed above, the Meridian term sheet includes a 90-day exclusivity period, and Penterra needs to make real-time commercial decisions about its distribution strategy in the Tri-State Area. Forcing Penterra to wait until June 2022 (or later, if the EDA auto-renews) before obtaining judicial resolution would inflict severe commercial harm on Penterra and would serve no legitimate judicial interest.
Fourth, the ripeness doctrine does not require parties to wait until a contract expires before seeking a declaratory judgment construing its terms. The whole point of declaratory relief is to resolve uncertainty during the operative period of the contract, so that the parties can conform their conduct to their actual legal obligations. See G.L. c. 231A, § 1 (permitting declarations "either before or after a breach or violation" of the relevant legal obligation).
C. Argument That the Business Litigation Session Lacks Jurisdiction
Anticipated argument. Vantage may raise a jurisdictional challenge to the Business Litigation Session of the Suffolk County Superior Court.
Response. Any such challenge would be meritless. The EDA's Section 14.5 provides for exclusive jurisdiction in the "state or federal courts located in the Commonwealth of Massachusetts." The Business Litigation Session of the Superior Court in Suffolk County is a state court located in Massachusetts, clearly within the scope of this forum-selection clause. Massachusetts courts routinely enforce forum-selection clauses of this type, and the Business Litigation Session is the appropriate venue for complex commercial disputes of this nature.
Moreover, Vantage is a Massachusetts limited liability company with its principal office at 75 Cabot Road, Suite 310, Medford, Massachusetts 02155. Vantage is thus subject to general jurisdiction in Massachusetts under G.L. c. 223A. Penterra maintains a registered agent in Massachusetts — CT Statutory Agent Services at 155 Federal Street, Suite 700, Boston, Massachusetts 02110 — and has consented to jurisdiction through the forum-selection clause. No jurisdictional challenge should succeed.
Additionally, Suffolk County is a proper venue because both Calderwood & Harkness LLP (1 Federal Street, 35th Floor, Boston, Massachusetts 02110) and Hargrove, Sinclair & Polk LLP (200 Ashbury Asset Advisors, Suite 1800, Boston, Massachusetts 02109) maintain offices in Suffolk County, and the forum-selection clause is most naturally read as contemplating litigation in Suffolk County, where the principal business courts of the Commonwealth are located.
D. Argument That the Matter Should Be Resolved in Arbitration or Another Forum
Anticipated argument. Vantage may argue that the dispute should be submitted to arbitration or resolved in another forum.
Response. The EDA does not contain an arbitration clause. Section 14.5 provides exclusively for litigation in the "state or federal courts located in the Commonwealth of Massachusetts." No competing forum exists, and Vantage has no basis for compelling arbitration or seeking transfer to another forum.
In the absence of an arbitration clause, Massachusetts courts will not compel arbitration of a contract dispute. See Plymouth-Carver Reg'l Sch. Dist. v. J. Farmer & Co., 407 Mass. 1006, 1007 (1990). The parties negotiated a specific dispute-resolution mechanism — litigation in Massachusetts courts — and that mechanism governs.
VII. Governing Law Considerations
Section 14.2 of the EDA provides that the agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, without regard to the principles of conflicts of law thereof. This choice-of-law clause is enforceable under Massachusetts law, see Restatement (Second) of Conflict of Laws § 187 (1971) (widely followed in Massachusetts), and its implications are significant for several aspects of this dispute.
First, the choice-of-law clause means that Massachusetts substantive law governs the interpretation of the EDA, including the interpretation of the Territory as defined in Section 2.1 and Exhibit A. Massachusetts follows the objective theory of contract interpretation, giving words their ordinary meaning and construing the contract as a whole. See Bank v. Thermo Elemental Inc., 451 Mass. 638, 648 (2008). Where the contract language is unambiguous, the court will enforce it according to its terms, without resort to extrinsic evidence. Id.
Second, Massachusetts law on written-modification clauses is favorable to Penterra's position. In Cambridge Biotech Corp. v. Pasteur Falveris Diagnostics, 433 Mass. 122 (2000), the Supreme Judicial Court held that written-modification clauses are generally enforceable and operate to bar implied oral modifications. This principle is directly relevant to Vantage's claim that the January 12, 2018 Kapoor Email constituted either "prior written consent" under Section 2.3 or an amendment to the Territory under Section 13.1. If the Kapoor Email does not satisfy the formalities required by the written-amendment clause — which requires a "written instrument signed by both parties" — then it cannot serve as either consent or an amendment, regardless of whatever informal representations may have been made. This point will be developed in full in a separate research memorandum on written-modification clauses and course of dealing under Massachusetts law, which is forthcoming.
Third, the choice-of-law clause eliminates any argument by Vantage that the law of New York, New Jersey, or Pennsylvania should apply to the territorial dispute. Vantage might otherwise have argued that because the disputed distribution activity took place in those states, the law of those states should govern the interpretation of the territorial provisions. The express choice of Massachusetts law forecloses this argument. This is particularly important because the law of some other jurisdictions may be less favorable to Penterra's position on the enforceability of written-modification clauses or the admissibility of course-of-dealing evidence.
Fourth, the "without regard to conflicts of law" language in Section 14.2 means that even if a Massachusetts conflict-of-laws analysis would otherwise point to the law of another state, Massachusetts law applies. This is a standard provision in sophisticated commercial agreements and reflects the parties' shared intention that the law of a single jurisdiction — the Commonwealth of Massachusetts — govern all disputes arising under the EDA.
VIII. Procedural Considerations
A. Venue
The complaint was filed in Suffolk County, Business Litigation Session, consistent with both Section 14.5 of the EDA and the practical considerations of the parties. Calderwood & Harkness LLP maintains its office at 1 Federal Street, 35th Floor, Boston, Massachusetts 02110, and Vantage's counsel at Hargrove, Sinclair & Polk LLP is located at 200 Ashbury Asset Advisors, Suite 1800, Boston, Massachusetts 02109. Both firms are located in Suffolk County, and the Business Litigation Session at the Suffolk County Superior Court is the designated venue for complex commercial litigation in the Commonwealth.
The case has been assigned to the Honorable Diane L. Costigan, Justice of the Superior Court. Judge Costigan has extensive experience with complex commercial matters in the Business Litigation Session and is well-versed in declaratory-judgment practice under G.L. c. 231A. The litigation team should be aware that Judge Costigan is known for adhering closely to scheduling orders and for expecting thorough briefing on dispositive motions, including comprehensive citation to the governing contractual provisions and applicable case law.
B. Counterclaims
On or about May 10, 2021, Vantage filed its Answer and Counterclaims, asserting the following three counterclaims against Penterra:
1. Breach of Contract. Vantage alleges that Penterra breached the EDA by threatening to appoint a competing distributor (Meridian) in the Tri-State Area, which Vantage claims is part of its exclusive Territory.
2. Breach of Implied Covenant of Good Faith and Fair Dealing. Vantage alleges that Penterra acted in bad faith by issuing the March 8, 2021 cease-and-desist letter and by pursuing the Meridian arrangement, allegedly in an effort to undermine Vantage's contractual rights.
3. Promissory Estoppel. Vantage alleges that it relied on representations made by Steven Kapoor (including but not limited to the January 12, 2018 email) to invest in Tri-State sales infrastructure and customer relationships, and that Penterra should be estopped from denying Vantage's territorial rights in those states.
Vantage seeks damages of $35 million across these counterclaims. Penterra filed its Answer to Counterclaims on June 4, 2021, denying all material allegations and raising affirmative defenses including the written-amendment requirement, the integration clause, failure to mitigate, and unclean hands.
The existence of Vantage's counterclaims does not defeat the declaratory-judgment action. To the contrary, the counterclaims confirm the existence of an actual controversy between the parties and underscore the need for judicial resolution. The declaratory-judgment action and the counterclaims will be resolved in the same proceeding, and the court's interpretation of the EDA's territorial provisions will be dispositive (or at least highly relevant) to both the declaratory claim and the counterclaims.
C. Standard of Review on Any Dispositive Motion
Cross-motions for summary judgment are well-suited to declaratory-judgment actions involving contract interpretation where the relevant documents are undisputed and the dispute turns on questions of law. See Mass. R. Civ. P. 56(c); Lenz v. CNA Assurance Co., 42 Mass. App. Ct. 260, 261 (1997) (summary judgment appropriate in declaratory-judgment action involving contract interpretation).
The court will construe the EDA's terms as a matter of law if the contract is unambiguous, applying standard principles of Massachusetts contract interpretation. Under these principles, the court gives words their ordinary meaning, construes the contract as a whole, and gives effect to all provisions so that no provision is rendered superfluous. See Bank v. Thermo Elemental Inc., 451 Mass. 638, 648 (2008). If the court finds the contract language ambiguous, extrinsic evidence — including the Kapoor Email, course of dealing, and course of performance — may be considered to resolve the ambiguity. See Robert Indus., Inc. v. Spence, 362 Mass. 751, 754 (1973).
The litigation team should begin preparing for summary judgment at an early stage, focusing on assembling the contractual documents (the EDA, Exhibit A, and any relevant amendments or correspondence) and developing the legal arguments for and against ambiguity.
IX. Conclusion and Recommendation
Based on the foregoing analysis, Penterra's declaratory-judgment action under G.L. c. 231A satisfies all threshold requirements for declaratory relief:
Actual Controversy. The parties hold irreconcilable positions on the scope of the Territory defined in the EDA, and those positions are backed by concrete actions and substantial financial stakes. Vantage has generated approximately $6.4 million in Tri-State revenues since September 2020. Penterra has issued a formal cease-and-desist demand. Vantage has threatened a $35 million counterclaim. The Meridian term sheet remains stalled. The controversy is actual, definite, and concrete.
Ripeness. The dispute is fit for judicial resolution because it presents a predominantly legal question of contract interpretation that can be resolved on the face of the EDA and the undisputed surrounding circumstances. No future contingency needs to occur; Vantage has already been distributing in the Tri-State Area for more than six months. Withholding review would cause ongoing and escalating commercial hardship to Penterra, including interference with the Meridian arrangement, exposure to Vantage's $35 million counterclaim, and uncertainty regarding Penterra's distribution strategy for a product that represents 22% of its consolidated revenue.
Standing. Penterra is a direct party to the EDA with a substantial and adverse interest in the scope of the Territory grant. Its legal rights, commercial operations, and financial exposure are all directly affected by the interpretation of the contractual provisions at issue.
Jurisdiction and Venue. The action is properly filed in the Business Litigation Session, Suffolk County, consistent with Section 14.5 of the EDA, Vantage's Massachusetts domicile, and Massachusetts procedural requirements. No jurisdictional or venue challenge should succeed.
Recommendations. Based on the foregoing, I recommend the following:
1. The litigation team should proceed to vigorously defend the ripeness and propriety of declaratory relief in anticipation of any threshold challenge by Vantage. If Vantage files a motion to dismiss under Mass. R. Civ. P. 12(b)(1) or 12(b)(6), or a motion for judgment on the pleadings, the team should be prepared to brief the issues identified in this memorandum, with particular emphasis on the actual-controversy and ripeness analyses.
2. The team should prepare for discovery, including the identification and collection of key documents (the EDA and all exhibits, the Kapoor Email of January 12, 2018, the March 8, 2021 cease-and-desist letter, the March 22, 2021 response from Hargrove, Sinclair & Polk LLP, the Meridian term sheet, and Penterra's internal correspondence regarding the Tri-State distribution dispute).
3. The team should begin developing the record for eventual cross-motions for summary judgment on the merits, focusing on the contract-interpretation arguments and the enforceability of the written-amendment clause.
4. A separate research memorandum on written-modification clauses and course of dealing under Massachusetts law is forthcoming. That memorandum will address the substance of Vantage's anticipated defense — including the claim that the Kapoor Email constitutes "prior written consent" or an amendment to the Territory — in the context of Cambridge Biotech Corp. v. Pasteur Falveris Diagnostics, 433 Mass. 122 (2000), and related authorities.
I am available to discuss this memorandum and its conclusions at the team's convenience.
X. Table of Authorities
Statutes
Cases
Other Authorities
Prepared by Patrick Gallagher, Working Associate, Calderwood & Harkness LLP. This memorandum is a privileged and confidential attorney work product. Distribution is restricted to the individuals identified in the header.
Authority | Citation
Massachusetts Declaratory Judgment Statute | G.L. c. 231A, §§ 1–3
Massachusetts Long-Arm Statute | G.L. c. 223A
Case | Citation | Relevance
Bunker Hill Distrib., Inc. v. District Attorney for the Suffolk Dist. | 376 Mass. 142 (1978) | "Actual controversy" standard; definite and concrete issues; liberal construction of c. 231A
Lockwood v. Commissioner of Revenue | 379 Mass. 674 (1980) | Ripeness; advisory-opinion prohibition
Massachusetts Ass'n of Indep. Agents & Brokers, Inc. v. Commissioner of Ins. | 373 Mass. 290 (1977) | Ripeness two-pronged inquiry; resolution without awaiting future contingency
Enos v. Secretary of Envtl. Affairs | 432 Mass. 132 (2000) | Standing; "direct, substantial and adverse" interest
Cambridge Biotech Corp. v. Pasteur Falveris Diagnostics | 433 Mass. 122 (2000) | Written-modification clauses; enforceability (full analysis reserved for separate memorandum)
Bank v. Thermo Elemental Inc. | 451 Mass. 638 (2008) | Contract interpretation; objective theory; unambiguous contracts construed as matter of law
Morrissey v. New England Deaconess Ass'n | 358 Mass. 764 (1971) | Liberal construction of declaratory-judgment statute
Boston Safe Deposit & Trust Co. v. Stratton | 259 Mass. 465 (1927) | Court discretion under c. 231A
Shapiro v. Sutherland | 64 Mass. App. Ct. 27 (2005) | Declaratory relief appropriate for contract-construction disputes
Boston v. Keene Corp. | 406 Mass. 301 (1989) | "Actual controversy" requirement
Robert Indus., Inc. v. Spence | 362 Mass. 751 (1973) | Extrinsic evidence for ambiguous contracts
Lenz v. CNA Assurance Co. | 42 Mass. App. Ct. 260 (1997) | Summary judgment in declaratory-judgment actions
Plymouth-Carver Reg'l Sch. Dist. v. J. Farmer & Co. | 407 Mass. 1006 (1990) | Arbitration; court will not compel absent agreement
Northpoint Casualty Group Life Ins. Co. v. Haworth | 300 U.S. 227 (1937) | Declaratory-judgment standing principles (federal analogy)
Sullivan v. Chief Justice for Admin. & Mgmt. of the Trial Court | 448 Mass. 15 (2006) | Declaratory relief to construe contractual instruments
Authority | Citation
Restatement (Second) of Conflict of Laws | § 187 (1971)
Massachusetts Rules of Civil Procedure | Rule 12(b)(1); Rule 12(b)(6); Rule 56(c)

INTERNAL MEMORANDUM

Record

Parties

Dates

Amounts